When patients or clinicians hear the term “unlicensed medicine”, it’s natural to worry. Does this mean the Medicines and Healthcare products Regulatory Agency (MHRA) — the UK’s regulator responsible for ensuring Find out more the safety, quality, and efficacy of medicines — has not examined it at all? The short answer is no.
In this post, we’ll explore key concepts behind licensed and unlicensed medicines, especially focusing on cannabis-based products prescribed in the UK. We will also clarify why the MHRA still sets strict supply rules even without a marketing authorisation, explain the role of named-patient specials, and highlight the pathways provided by authorised manufacturers and importers.
Understanding Licensed vs Unlicensed Medicines
First, it is important to define the difference between a licensed medicine and an unlicensed medicine, as these terms often cause confusion.
Licensed Medicines
A licensed medicine, also called a market authorised medicine, has been approved by the MHRA — or the European Medicines Agency (EMA) before Brexit — following a rigorous evaluation process. The manufacturer must submit data demonstrating the medicine’s quality, safety, and efficacy in specific uses. Once authorised, the medicine’s licence will Browse around this site include the approved indications, dosing, formulation, and packaging.
This system ensures that products readily available in UK pharmacies meet consistent, high standards. Healthcare professionals and patients can be confident in the robustness of the regulatory review behind licensed medicines.
Unlicensed Medicines
In contrast, an unlicensed medicine is one that does not have a marketing authorisation from the MHRA. This means it has not passed the same formal licensing procedure. However, this does not mean the MHRA has ignored the product or left it unchecked.
The MHRA does set supply rules for unlicensed medicines to safeguard patient safety. These rules require that unlicensed medicines are:
- manufactured according to Good Manufacturing Practice (GMP) or imported by authorised suppliers; prescribed only where no suitable licensed alternative exists; supplied with adequate information about safety and quality; used under clinical supervision, usually by specialist prescribers.
Named-Patient Unlicensed Specials: What Are They?
The most common use of unlicensed cannabis-based products in the UK is as named-patient specials. This is a legal framework that allows a healthcare professional to request a medicine prepared specifically for an individual patient when no licensed alternative is available.
Named-patient specials are often produced by authorised manufacturers or importers, who must comply with specific MHRA standards for quality, traceability, and storage during manufacture and delivery.
Both Releaf cannabis clinic and medicalcannabis.co.uk direct patients through this route. They work with authorised suppliers to provide standardized cannabis-based products tailored for specialist prescribing.
Why Specialist Prescribing Matters
The MHRA requires specialist clinicians to prescribe unlicensed cannabis medicines under this framework. That is because unlicensed products have not gone through the full clinical trial process for efficacy and safety in the licensed indications. Specialist knowledge helps navigate issues like:
- appropriate dosing and titration; monitoring for adverse effects; assessing clinical benefit for the individual patient; managing drug interactions and comorbidities.
Authorised Manufacturers and Importers: Upholding Quality Despite “Unlicensed” Status
The term “unlicensed” can imply an absence of regulatory oversight. In reality, the MHRA tightly controls who can supply such medicines in the UK, especially cannabis-based products.
Only manufacturers and importers with valid MHRA licences can legally supply unlicensed specials. They must comply with:
- Good Manufacturing Practice (GMP): the set of guidelines ensuring products are consistently produced and controlled to quality standards. Batch testing: to verify identity, potency, purity, and microbial contamination. Storage and transport controls: to maintain product integrity from manufacturer to patient. Documentation and traceability: so each batch is fully accounted for and can be recalled if needed.
Despite lacking a marketing authorisation, unlicensed medicines supplied like this meet high safety and quality benchmarks due to these mandatory rules.
MHRA Oversight Without Marketing Authorisation
It is vital to understand that while the MHRA has not authorised the medicine for general use (hence no marketing authorisation), it actively regulates the supply chain for unlicensed specials. This includes inspecting manufacturers and handling safety reporting requirements.
This ensures that patients and clinicians are not exposed to untested or poorly made products simply because a medicine is “unlicensed.”
The Practical Impact for Patients and Clinicians
So what does all this mean in practical terms? Here are some key takeaways:
“Unlicensed” does not mean unsafe or unregulated. The MHRA sets clear supply and manufacturing rules to protect patients. Access to unlicensed products typically requires specialist prescribing. Clinics like the Releaf cannabis clinic help guide patients safely through these pathways. Named-patient specials are personalised medicines made for an individual’s clinical needs. Unlike licensed medicines, they do not have formal product licences but follow stringent manufacturing rules. Authorised importers and manufacturers are key gatekeepers of quality. They must comply with MHRA licences and standards even though the medicine remains unlicensed.Additional Resources
For healthcare professionals and curious patients who want to learn more about MHRA regulations and cannabis-based treatments, consider these options:
- Pharma Journal's 'Listen' audio option — An accessible way to absorb expert insights while multitasking. Site subscription form — Stay informed with the latest evidence-based updates in pharmaceutical regulation and clinical practice.
Summary Table: Licensed vs Unlicensed Medicines
Aspect Licensed Medicine Unlicensed Medicine (Named-Patient Special) Regulatory Status MHRA-issued marketing authorisation after clinical trials No marketing authorisation; supply regulated by MHRA rules Manufacturer Requirements GMP, batch testing, full dossier submission GMP compliance if manufactured/imported by MHRA-licensed supplier Prescribing General practitioners and specialists Specialist prescribing, often via private clinics like Releaf or medicalcannabis.co.uk Safety Assurances Based on clinical trials and post-market surveillance Based on manufacturing standards and specialist clinical oversight Patient Access Available via NHS and community pharmacies Named-patient basis, often private clinics or specialist hospital teamsFinal Thoughts
The label “unlicensed” may sound daunting at first, but it does not imply that products are ignored or unregulated by the MHRA. On the contrary, the MHRA carefully sets supply rules to ensure unlicensed medicines meet high manufacturing and safety standards — just without a full marketing authorisation.
In the fast-evolving field of medical cannabis, specialist clinics such as Releaf cannabis clinic and service providers like medicalcannabis.co.uk play an important role in navigating these regulatory pathways. By partnering with authorised manufacturers and importers and supporting specialist prescribing, these providers help patients access safe, quality treatments even when licensed options are unavailable.
Always consult a healthcare professional familiar with cannabis-based medicines before starting any treatment. Staying informed helps you ask the right questions about licensing, safety, and clinical oversight.